Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02666417
Other study ID # FeGOS_KP
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2016
Est. completion date December 2016

Study information

Verified date July 2018
Source Swiss Federal Institute of Technology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Infants and young children in sub-Saharan Africa have high rates of iron deficiency anemia (IDA), which adversely affects their growth and cognitive development. In-home iron fortification of complementary foods using micronutrient powders (MNPs) reduces risk for IDA. However, in areas with a high burden of infectious diseases iron may increase the risk of unfavorable gut microbiota composition possibly influencing diarrhea prevalence. Thus, there is an urgent need to find safer formulations of iron fortification for African infants. The investigators recently finished a randomized, double blind controlled intervention trial in Kenya where the investigators tested whether the addition of galacto-oligosaccharides (GOS) in a MNP containing 5 mg of iron protects against the adverse effects of the iron on the infant gut microbiome and gut inflammation (ClincalTrails.gov Identifier: NCT02118402). Prebiotics are also potential enhancers of colonic iron absorption. Therefore, to complement the intervention study, the present study will compare iron absorption from the combination of sodium iron EDTA (NaFeEDTA) and ferrous fumarate (FeFum) with and without prior consumption GOS or 3 weeks. The investigators will enroll 80 Kenyan infants from Kwale County, aged 6-14 months of whom 40 infants will consume maize porridge blended with MNP containing iron and 40 infants will receive a porridge mixed with MNP containing iron+GOS. After 3 weeks of MNP consumption, two test meals will be fed on two consecutive mornings, and will consist of maize porridge containing isotopically labeled FeFum and NaFeEDTA or isotopically labeled ferrous sulfate (FeSO₄), respectively. Fourteen days after the second test meal administration, a whole blood sample will be collected by venipuncture for iron isotopic analysis. Iron and inflammation status parameter will be determined at baseline and endpoint. A stool sample will be collected at baseline and on the first test meal day. The gut microbiome, fecal pH and fecal SCFAs profile will be analyzed. Knowing the expected iron absorption from the iron and GOS containing MNP will inform decisions on type of iron compound and dosing regimens for MNPs to allow the lowest iron dose to be used but still cover the infant requirement for absorbed iron.


Description:

Iron absorption from two iron-fortified maize-based test meals will be measured in two groups of 40 infants (total N=80). Infants will be recruited at Msambweni District Hospital and communities served by Msambweni District Hospital in southern coastal Kenya. In group 1, iron absorption is measured after 3 weeks of MNP consumption containing 5 mg iron in form of NaFeEDTA (2.5 g) and FeFum (2.5 g) but no GOS. In group 2, iron absorption is measured after 3 weeks of MNP consumption containing 5 mg iron in form of NaFeEDTA (2.5 g) and FeFum (2.5 g) and 7.5 g GOS. Iron absorption is measured as the incorporation of stable isotopes into erythrocytes at least 14 days after the test meal administration.

At baseline, a blood sample will be collected from potential study participants for the determination of the following iron and inflammation status parameters: hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), zinc protoporphyrin (ZnPP), C-reactive protein (CRP), alpha-1-acid glycoprotein (AGP). Anthropometrics (height, weight, mid-upper arm and head circumference) will be measured, and demographics, the medical history and the feeding habits will be assessed using a questionnaire. On day 1, infants will be enrolled and randomized into the two groups, and then start the intervention. The infants will consume 1 MNP sachet added to maize porridge per day for a total of 5 weeks. A stool sample will be collected on day 1 for the determination of gut microbiota composition, fecal pH and fecal SCFAs. After 3 weeks of MNP consumption, the two isotopically labelled test meals will be fed to the infants by their caregivers under supervision of the research team on two consecutive mornings between 7 and 8 am. Test meal A will contain 2.5 mg 57Fe in form of FeFum and 2.5 mg iron as NaFeEDTA (given as 1.5 mg 56Fe and 1 mg 58Fe). Test meal B will contain 5 mg iron in form of FeSO₄ (3 mg of 56Fe and 2 mg of 54Fe). The test meals will consist of maize porridge (5-10% dry weight) and mineral water (30 ml) and will be randomly administered on the two consecutive days (AB or BA). Overnight, only breast milk will be allowed to the infant and no breast milk will be given at least 3 h before test meal administration. Infants will not be allowed to eat or drink for 2 h after the test meal. On the day of the first test meal, a stool sample will be collected and analyzed for gut microbiota composition, fecal pH and fecal SCFAs. Fourteen days after the second test meal administration, 3 ml of whole blood will be collected by venipuncture for iron isotopic analysis and iron and inflammation status. Anthropometrics and the baseline questionnaire will be repeated. Compliance of MNP consumption and adverse event reporting (morbidity monitoring) will be done during weekly visits of the infants.

In a follow-on study, iron absorption from the two above described mentioned iron-fortified maize-based test meals will be measured in 24 infants aged 6-12 months without pre-feeding of GOS. All procedures will be done identical as described above.


Other known NCT identifiers
  • NCT03357510

Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date December 2016
Est. primary completion date April 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months to 14 Months
Eligibility Inclusion Criteria:

- Age of 6-14 months at baseline

- Assessment of good health as assessed by professional staff at Msambweni District Hospital

- Willingness of their caregiver to provide informed consent

Exclusion Criteria:

- Hemoglobin <70 g/L ; these infants will be referred for treatment according to local standard of care.

- Severe underweight (Z-score weight-for-age <-3) and /or severe wasting (Z-score weight-for-height<-3)

- Chronic or acute illness or other conditions that in the opinion of the Principle Investigator (PI) or co-researchers would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol

- Participants taking part in other studies requiring the drawing of blood

- Participants who are taking iron-containing food supplements or tablets/drops

- Participants who are taking antibiotics

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Fortified maize porridge (MNP+iron)
Maize porridge will be home-fortified with the MNP + iron. Maize porridge for the test meal will be fortified with labelled iron compounds
Fortified maize porridge (MNP+iron+GOS)
Maize porridge will be home-fortified with the MNP + iron + GOS. Maize porridge for the test meal will be fortified with labelled iron compounds

Locations

Country Name City State
Kenya Msambweni District Hopsital Msambweni Kwale County

Sponsors (4)

Lead Sponsor Collaborator
Swiss Federal Institute of Technology International Centre for Behavioural Studies, Jomo Kenyatta University of Agriculture and Technology, Msambweni District Hospital

Country where clinical trial is conducted

Kenya, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in the isotopic ratio of iron in blood at week 5 The change in the isotopic ratio of iron will be measured after the administration of test meals including iron isotopes. Baseline and Week 5
Secondary Gut microbiome composition The changes in the gut microbiome composition from baseline to week 3 will be compared among the two groups and correlated to the iron absorption from the test meal. Baseline and Week 3
Secondary Fecal pH The changes in fecal pH from baseline to week 3 will be compared among the two groups and correlated to the iron absorption from the test meal. Baseline and Week 3
Secondary Fecal short chain fatty acids (SCFAs) The changes in SCFAs from baseline to week 3 will be compared among the two groups and correlated to the iron absorption from the test meal. Baseline and Week 3
Secondary H.pylori H.pylori infection as determinant of iron absorption Baseline
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03516734 - Iron-fortified Lentils to Improve Iron (Fe) Status in Bangladesh N/A
Completed NCT02570854 - A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients Phase 1
Completed NCT02887963 - Epidemiological Study of Iron Deficiency and Iron Deficiency Anemia in Chinese Pregnant Women N/A
Completed NCT00534144 - Comparison Between Effects of Two Iron Preparations on Protein in the Urine Phase 1
Completed NCT00224081 - DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin) Phase 4
Recruiting NCT02999217 - Intravenous Iron for Correction of Anaemia After Colorectal Surgery Phase 4
Recruiting NCT04351607 - Preoperative Supplementation of Sucrosomal Iron as Hematopoietic Support. N/A
Completed NCT04163406 - The Effect of Human Milk Oligosaccharides and Galacto-oligosaccharides on Iron Absorption in Kenyan Infants N/A
Completed NCT02365103 - Tea Consumption and Iron Bioavailability in Women Using a Stable Isotope N/A
Completed NCT00536666 - A Study of Iron Oligosaccharide in Chronic Kidney Disease Patients Phase 3
Completed NCT02310607 - Non-invasive Optical Detection of Iron Deficiency N/A
Completed NCT01755455 - Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis N/A
Terminated NCT00929409 - Controlled Randomised Trial of Ferric Carboxymaltose and Oral Iron to Treat Postpartum Anemia Phase 2/Phase 3
Completed NCT00354692 - Effect of Two Iron Preparations on Protein in the Urine Phase 4
Recruiting NCT05628896 - Efficacy of a Preoperative Anaemia Clinic in Patients Undergoing Elective Abdominal Surgery
Completed NCT02892461 - Effect of Umbilical Cord Milking on Iron Related Health Outcomes for Cesarean-Delivered Infants N/A
Completed NCT02905539 - A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer Phase 4
Not yet recruiting NCT01840384 - Efficacy Study of Multiple Micro Nutrients Supplementation N/A
Recruiting NCT00125996 - Effect of Intravenous Ferrous Sucrose on Exercise Capacity in Chronic Heart Failure Phase 1/Phase 2
Not yet recruiting NCT04975074 - Iron Deficiency Anemia in Twin Pregnancies Phase 4